Cogent Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cogent Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($328.94M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($255.86M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($192.41M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($140.24M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($72.27M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2020 | ($74.81M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2019 | $2.30M | Mar 26, 2020 |
| FY2019 | Sep 30, 2019 | ($11.92M) | Mar 26, 2020 |
| FY2019 | Jun 30, 2019 | ($10.52M) | Mar 26, 2020 |
| FY2019 | Mar 31, 2019 | ($11.69M) | Mar 26, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($333.36M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($275.94M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($208.13M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($147.84M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($75.55M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2020 | ($82.20M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2019 | $2.24M | Mar 26, 2020 |
| FY2019 | Sep 30, 2019 | ($12.04M) | Mar 26, 2020 |
| FY2019 | Jun 30, 2019 | ($10.54M) | Mar 26, 2020 |
| FY2019 | Mar 31, 2019 | ($11.84M) | Mar 26, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.78M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $232.66M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $173.76M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $121.63M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $55.91M | Feb 26, 2024 |
| FY2021 | Dec 31, 2020 | $25.74M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $43.71M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $38.29M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $29.83M | Mar 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($264.44M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($207.79M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($153.62M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($118.64M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($58.76M) | Feb 26, 2024 |
| FY2021 | Dec 31, 2020 | ($35.85M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($41.51M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($32.49M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($25.84M) | Mar 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $573.0K | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $6.86M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.72M | Feb 26, 2024 |
| FY2020 | Dec 31, 2019 | $33.0K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $549.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $912.0K | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $937.61M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $327.90M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $313.44M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $300.81M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $232.09M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $250.92M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $49.42M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $85.93M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $49.12M | Mar 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.24M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $71.61M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $55.64M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $45.08M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $17.91M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $16.25M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $17.66M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $25.69M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $20.81M | Mar 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $636.37M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $256.29M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $257.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $255.74M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $214.18M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $234.67M | Feb 26, 2024 |
| FY2021 | Dec 31, 2019 | $31.76M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $60.23M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($48.85M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | ($24.70M) | Mar 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.19B) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($859.48M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($603.62M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($411.21M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($270.97M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($198.70M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($123.89M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($92.06M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($51.34M) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $312.01M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $98.17M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $53.23M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $139.89M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $219.68M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $242.19M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $37.42M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $55.67M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $28.27M | Mar 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.90M | Feb 17, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2019 | Dec 31, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2019 | Dec 31, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 26, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 160.98M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 110.46M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 86.12M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 69.89M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 43.81M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 32.35M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 7.67M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 30.06M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 10.20M | Mar 28, 2019 |